Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Faculty of Medicine, University of Bergen, Horten, Norway.
Virol J. 2021 May 12;18(1):98. doi: 10.1186/s12985-021-01571-7.
In recent years, oncolytic viruses (OVs) have drawn attention as a novel therapy to various types of cancers, both in clinical and preclinical cancer studies all around the world. Consequently, researchers have been actively working on enhancing cancer therapy since the early twentieth century. This study presents a systematic review of the literature on OVs, discusses underlying research clusters and, presents future directions of OVs research.
A total of 1626 published articles related to OVs as cancer therapy were obtained from the Web of Science (WoS) database published between January 2000 and March 2020. Various aspects of OVs research, including the countries/territories, institutions, journals, authors, citations, research areas, and content analysis to find trending and emerging topics, were analysed using the bibliometrix package in the R-software.
In terms of the number of publications, the USA based researchers were the most productive (n = 611) followed by Chinese (n = 197), and Canadian (n = 153) researchers. The Molecular Therapy journal ranked first both in terms of the number of publications (n = 133) and local citations (n = 1384). The most prominent institution was Mayo Clinic from the USA (n = 117) followed by the University of Ottawa from Canada (n = 72), and the University of Helsinki from Finland (n = 63). The most impactful author was Bell J.C with the highest number of articles (n = 67) and total local citations (n = 885). The most impactful article was published in the Cell journal. In addition, the latest OVs research mainly builds on four research clusters.
The domain of OVs research has increased at a rapid rate from 2000 to 2020. Based on the synthesis of reviewed studies, adenovirus, herpes simplex virus, reovirus, and Newcastle disease virus have shown potent anti-cancer activity. Developed countries such as the USA, Canada, the UK, and Finland were the most productive, hence, contributed most to this field. Further collaboration will help improve the clinical research translation of this therapy and bring benefits to cancer patients worldwide.
近年来，溶瘤病毒（OVs）作为一种新型疗法，在全球的临床和临床前癌症研究中引起了广泛关注。因此，自 20 世纪初以来，研究人员一直在积极致力于增强癌症治疗。本研究对 OVs 的文献进行了系统综述，讨论了潜在的研究集群，并提出了 OVs 研究的未来方向。
从 Web of Science（WoS）数据库中获取了 2000 年 1 月至 2020 年 3 月期间发表的 1626 篇与 OVs 作为癌症治疗相关的文章。使用 R 软件中的 bibliometrix 包分析了 OVs 研究的各个方面，包括国家/地区、机构、期刊、作者、引文、研究领域和内容分析，以发现趋势和新兴主题。
就出版物数量而言，美国的研究人员（n=611）最为活跃，其次是中国（n=197）和加拿大（n=153）的研究人员。Molecular Therapy 杂志在出版物数量（n=133）和本地引文数量（n=1384）方面均排名第一。最突出的机构是美国的梅奥诊所（n=117），其次是加拿大的渥太华大学（n=72）和芬兰的赫尔辛基大学（n=63）。最有影响力的作者是 Bell J.C.，他的文章数量（n=67）和总本地引文数量（n=885）最多。最有影响力的文章发表在 Cell 杂志上。此外，最新的 OVs 研究主要基于四个研究集群。
从 2000 年到 2020 年，OVs 研究领域的发展速度非常快。基于综述研究的综合分析，腺病毒、单纯疱疹病毒、呼肠孤病毒和新城疫病毒已显示出强大的抗癌活性。美国、加拿大、英国和芬兰等发达国家是最有成效的国家，因此对这一领域的贡献最大。进一步的合作将有助于改善这种疗法的临床研究转化，并为全球癌症患者带来益处。
